A Young dMMR Colorectal Cancer Patient Shares His Healing Journey | Panda Patient Stories

After a colorectal cancer diagnosis at 36, Mr. Zhao sought care in Beijing and was found to have a rare dMMR subtype. Through self-study, he understood its unique characteristics and chose a clinical trial over immediate surgery. After three treatment cycles, he underwent surgery, and post-operative pathology confirmed a pathological complete response (pCR).

Throughout his treatment, he continued working, maintained a positive lifestyle, and warmly supported fellow patients. Even after a cancer diagnosis, life can still shine brightly.

Many assume dMMR patients are "chosen ones" whose treatment will be smooth sailing. In reality, due to limited awareness among both doctors and patients, it is not uncommon for dMMR patients to face repeated setbacks, ultimately reaching a critical, irreversible state.

Mr. Zhao did not rely blindly on a favorable genetic subtype for a cure. Instead, he took his destiny into his own hands through continuous learning. By constantly practicing and reflecting, he optimized his medical consultation process and efficiency, avoiding any unnecessary detours.

After achieving positive outcomes in his own treatment, he served as a role model to help doctors communicate with patients, easing their concerns and encouraging them to accept advanced clinical trial therapies.

The Panda MSI-H Lynch Syndrome community now has 8 groups with nearly 4,000 dMMR/MSI-H patients. Please scan the QR code at the end of this article to join.

👇🏻 Scan the QR code below to review past patient education videos.

Small Donation Channel

Charity China Certification

Patient Stories | Click the text to jump directly

Notes from a Middle-Aged Beijing Man Fighting Advanced Colon Cancer | The Anti-Cancer "Black Magic" of a Panda Star | A-Ming: Two Years Accompanying My Mom Through Liver and Lung Metastatic Colon Cancer Treatment | Xiao Li: A Patient's Self-Narrative on Fighting Cancer | Sister Xiuxiu: The Treatment Journey for Colon Cancer with Liver and Ovarian Metastases | Brother Guo: The Resilient Treatment Path for Colon Cancer with Peritoneal Metastasis | Naonao: The Self-Rescue Journey After Colon Cancer Recurrence at 27 | Sister Tudou: A 7-Year Battle Against Colon Cancer with Lung and Brain Metastases | Jin Xia: A 4-Year Treatment Journey for HER2-Positive Gastric Cancer | Mickey: The Late-Stage Gastric Cancer Treatment Path at 31 | Alison: Treatment for HER2-Positive Advanced Colon Cancer | From Stage IV Gastric Cancer to Complete Remission | 78 Liver Metastases Do Not Mean a Death Sentence | The Late-Stage Cancer Patient Who Entered the ICU Due to Infection Is Now Tumor-Free | The Harsh Truth Behind Treatment Value: Why Some Patients Are Advised Against Seeking Care in Beijing, Shanghai, or Guangzhou | Anti-Cancer Blogger Fengzi Passes Away: Who Will Care for Young Patients Fighting Cancer Alone? | Panda & Friends | Nine Years of Fighting Advanced Cancer: Happiness Still Found Me | Patient Story | At 33, After Being Given a "Death Sentence" by Cancer | The Solo Anti-Cancer Journey of a Post-85s Generation: To Be Continued (Part 1) | Thirteen Years Battling Advanced Gastric Cancer: Four Surgeries and Three Ostomies, Yet Still a Romantic Life | Patient Story | A Hellish Start with Advanced Colon Cancer Can Still Yield a Tumor-Free Miracle | Patient Story | The Joyful Life of a Lynch Syndrome Colon Cancer Patient | Patient Story

Doctor-Patient Communication | Click the text to jump directly

Shen Lin, Peking University Cancer Hospital: 2023 Advances in Immunotherapy for Colorectal Cancer | Step-by-Step Guide for Colon and Gastric Cancer Patients on How to Seek Medical Care

Xing Baocai, Peking University Cancer Hospital: Doctor-Patient Communication on Liver Metastasis in Colorectal Cancer

Chen Gong, Sun Yat-sen University Cancer Center, Guangzhou: Whether to Proceed Directly to Surgery After Colorectal Cancer Diagnosis

Xiao Jian, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou: Chemotherapy, Targeted Therapy, and Immunotherapy for Advanced Gastric Cancer